

1 **Period2-mediated downregulation of ERK/MAPK**

2 **phosphorylation in nasopharyngeal carcinoma**

3 Zhijuan Zhang^{1¶}, Zheng Ma^{1¶}, Jing Kang¹, Jing Yang¹, Qianru Xu², Xinran
4 Niu², Xiaoya Luo², Jingyuan Wang³, Hailiang Li^{4*}, Li Hou^{1*}

5 ¹Department of Otolaryngology, General Hospital of Ningxia Medical
6 University, Yinchuan, China;

7 ²School of Clinical Medicine, Ningxia Medical University, Yinchuan,
8 China;

9 ³School of Clinical Medicine, Hainan Medical College, Hainan, China;

10 ⁴Department of Radiotherapy, General Hospital of Ningxia Medical
11 University, Yinchuan, China;

12 * Corresponding author

13 Name: Hailiang Li; E-mail: hailiang1995@163.com

14 Name: Li Hou; E-mail: hlah199@sina.com

15 ¶ These authors contributed equally to this work

16 **Abstract**

17 Purpose: Period2 (PER2) is associated with the occurrence and
18 development of nasopharyngeal carcinoma (NPC); however, its

19 mechanism(s) of action underlying NPC carcinogenesis remains unclear.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Method: In this study, differentially expressed proteins were identified via
21 proteomics. The cells were infected with Lentivirus and divided into two
22 groups: normal control group (Control) and *PER2* overexpression
23 Lentivirus-infected group (*PER2*-OE). Western blot was used to detect
24 ERK and p-ERK expression in the two groups. Immunohistochemistry was
25 used to further detect *PER2* and p-ERK expression in human NPC samples,
26 and the correlations between *PER2*, p-ERK and clinical NPC
27 characteristics were analysed. Result: Statistical analysis revealed that
28 MAPK3 (ERK) was among the top 20 differentially expressed proteins,
29 *PER2* overexpression and control samples were significantly different
30 ($P < 0.05$). The western blot results showed that *PER2* overexpression
31 downregulated p-ERK protein expression. Significant differences ($P <$
32 0.05) were observed in the proportions of cells which expressed *PER2* and
33 p-ERK between NPC tissues and normal nasopharyngeal mucosa samples.
34 Conclusion: Overexpression of *PER2* downregulated the expression of p-
35 ERK. In NPC tissues, *PER2* protein was expressed at low levels, whereas
36 p-ERK protein was highly expressed, and these trends are closely related to
37 the occurrence and development of NPC.

38 **Keywords:** *Nasopharyngeal carcinoma, Period 2, Circadian rhythm,*
39 *ERK/MAPK signal path*

40 **Introduction**

41 Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head
42 and neck that originates from the nasopharyngeal mucosa and is typically
43 found in the nasopharyngeal crypts. Non-keratinised squamous cell
44 carcinoma accounts for >95% of all pathologically typed carcinomas (1, 2).
45 As these malignancies typically do not manifest clinically in the early
46 stages, most patients are diagnosed at an advanced stage (3). Radiotherapy
47 and chemotherapy are the preferred treatments for NPC. Recently, it has
48 been shown that circadian clock genes are related to the occurrence and
49 development of tumours and their sensitivity to anticancer drugs and
50 radiation (4-6). *Period2* (*PER2*), a core circadian clock gene, plays a
51 significant tumour-suppressive role in most cancer cells and is related to
52 proliferation, invasion, metastasis, cell cycle distribution, apoptosis, DNA
53 damage and repair, transcriptional reprogramming, and anticancer drug
54 and/or radiation sensitivity (7-11). *PER2* downregulation increases the
55 radiation resistance of cells and E1A- and RAS-driven oncogenic
56 transformation (12). Circadian clock genes (*PERs*) are reportedly
57 associated with NPC prognosis (13); however, the role(s) of *PER2* in NPC
58 has not been reported. In our previous study (14), we used qPCR to screen
59 the expression of biological rhythm genes including *PER1*, *PER2*, *PER3*,
60 *BMAL1*, *CLOCK*, *CK1*, *TIMLESS*, and *CRY2* in NPC tissues. The results
61 showed that *PER2* expression differed the most between groups. *PER2*
62 expression was lower in NPC cell lines than in normal nasopharyngeal

63 mucosa. By constructing a *PER2*-overexpressing NPC cell line, we further
64 found that *PER2* overexpression could inhibit the proliferation, migration,
65 and invasion of NPC, as well as its tumorigenicity in nude mice. *PER2*
66 expression inhibits cell cycle progression in NPC cells and promotes
67 apoptosis. *PER2* acts as a tumour suppressor in NPC. Therefore, the
68 purpose of this study was to further explore the molecular mechanisms
69 through which *PER2* regulates the biological behaviour of NPC, thereby
70 providing novel insights into the clinical treatment of NPC to optimise
71 antitumor treatments and improve the quality of life for patients with NPC.

72 **Materials and methods**

73 **Materials**

74 **Cell line**

75 CNE2, a human NPC cell line, was purchased from Shanghai
76 Zhongqiao Xinzhou Biotechnology Co., Ltd.

77 **PER2-overexpressing lentivirus**

78 The *PER2*-overexpressing lentivirus used in this experiment was
79 purchased from Shanghai Jikai Biological Company.

80 **Clinical samples**

81 Paraffin-embedded specimens of 66 NPC tissues and 29
82 nasopharyngeal mucosa tissues collected and stored at the General Hospital
83 of Ningxia Medical University between January 2016 and November 2018

84 were used in this study (The data was accessed on May 15, 2022). None of
85 the patients had a history of malignant disease or an additional primary
86 tumour and had not received radiotherapy, chemotherapy, or surgical
87 treatments. Histopathological analyses confirmed that the tumour tissue
88 specimens were nasopharyngeal squamous cell carcinomas. Clinical NPC
89 staging was performed according to the UICC/AJCC staging system (8th
90 edition, 2016).

91 **Methods**

92 **Cell culture**

93 The frozen cells were removed from a liquid nitrogen tank, quickly
94 thawed in a 37 °C water bath, and centrifuged at 1000 rpm for 3-5 minutes.
95 The supernatant was discarded, and fresh medium containing RPMI-1640
96 was added. Cells were resuspended and diluted based on cell density before
97 being inoculated into a 10 cm culture flask and cultured in a 37 ° C cell
98 incubator (5% CO₂). Cell growth was observed microscopically, and the
99 medium was changed every 2–3 days or based on cell growth.

100 *Transfection of NPC cells with PER2-overexpressing lentivirus*

101 NPC cells in the logarithmic growth stage were selected, and cell
102 suspensions were prepared. The cells were counted, and the cell density
103 was adjusted to 5×10^4 cells/mL in RPMI-1640 complete medium. Briefly,
104 1 mL of each cell suspension was inoculated into 6-well plates. Following
105 a 24 h incubation, the fresh medium was replaced with 90 µL of the diluted

106 transfected lentivirus solution, which had an multiplicity of infection
107 (MOI) value of 20. Cell morphology was observed, and the fluorescence of
108 the transfected cells in each group was observed under an inverted
109 fluorescence microscope to evaluate the efficiency of viral transfection.
110 Cells were infected with Lentivirus and divided into two groups: normal
111 control group (Control) and *PER2*-overexpressing Lentivirus-infected
112 group (*PER2*-OE).

113 **Proteomics**

114 Cultured cells were subjected to protein extraction, enzymatic
115 hydrolysis, and peptide desalting. A chromatogram of the total ion flow
116 was obtained using the mass spectrometry signal. The screening parameters
117 were set, and MS data were fed into Proteome Discoverer (PD version 2.1,
118 Thermo Fisher Scientific) to screen the MS spectrum and conduct
119 quantitative analyses on the output according to the subsequent search
120 results and spectrum. The UniProt database (Homo sapiens, 201902, entry
121 20431; link: <http://www.uniprot.org/uniprot/?query=taxonomy:9606>) was
122 used for analysis.

123 **Western blot**

124 ERK and p-ERK protein expression was detected in the two groups.
125 Western blotting was performed according to the manufacturer's
126 instructions. Total proteins from cells in each group were extracted, and
127 their concentrations were determined. The proteins were subjected to

128 polyacrylamide gel electrophoresis (SDS-PAGE), membrane transfer,
129 immune reactions, and exposure. The films were scanned, and the optical
130 density of the target band was analysed using a gel image processing
131 system (Gel-Pro-Analyzer software).

132 **Immunohistochemistry**

133 The standard SP method was used for immunohistochemical
134 detection. The stained tissue sections were independently reviewed and
135 scored by two experienced pathologists. Five high-power mirror fields
136 were randomly selected from each slice to obtain the results. The staining
137 intensity was categorised as brown (grade 3), yellow (grade 2), light yellow
138 (grade 1), and unstained (grade 0) and scored according to the percentage
139 of positively stained cells: $\leq 5\%$ (0 points), 6%–25% (1 point), 26%–50% (2
140 points), and $\geq 51\%$ (3 points). The score for each specimen was calculated
141 by multiplying the staining intensity grading score by the staining degree
142 score. A score of 0–2 was considered negative for protein expression,
143 whereas a score >2 was considered positive.

144 **Statistical analyses**

145 SPSS V22.0 (IBM, USA) statistical analysis software was used. Data
146 are presented as the mean \pm standard deviation, and Student's t-tests were
147 used to compare results between groups. Chi-square tests were used for
148 analysis of variance. One-way analysis of variance (ANOVA) was also
149 used to compare data between groups. $P \leq 0.05$ was considered statistically

150 significant.

151 **Results**

152 **PER2 downregulates ERK/MAPK phosphorylation in NPC** 153 **cell lines.**

154 Based on our proteomic analysis, 174 genes were differentially
155 expressed between the *PER2*-overexpressing and control groups, of which
156 140 were upregulated and 34 were downregulated (Fig 1). The top 20
157 differentially expressed proteins included MAPK3 (ERK), an important
158 molecule in the MAPK signalling pathway, which had a 4-fold difference
159 in expression between the *PER2*-overexpressing and control groups ($P <$
160 0.05) (Table 1, Fig 2). Further validation experiments (via WB) of ERK
161 and p-ERK expression between the two groups showed no significant
162 changes in ERK levels; however, p-ERK protein expression levels were
163 downregulated. The results showed that overexpression of *PER2*
164 downregulated the expression of p-ERK (Fig 3).

165 Table 1 MAPK3 expression in *PER2* overexpression group and control
166 group

Protein name	log2	P
MAPK3	2.06	0.03

167 **PER2 and p-ERK expression in human NPC and its**

168 **clinical correlations**

169 To further understand the role of PER2 and p-ERK in NPC tissues, 66
170 NPC tissues and 29 normal nasopharyngeal mucosa paraffin specimens
171 were selected for immunohistochemical detection. A significant difference
172 was observed in the positive expression rates of PER2 in NPC tissues
173 (15.15%, 10/66) when compared to normal nasopharyngeal mucosa
174 (89.66%, 26/29) ($P < 0.05$) (Table 2). PER2 protein was mostly localised in
175 the nucleus (followed by the cytoplasm) in NPC tissues and normal
176 nasopharyngeal mucosa. Yellow or brownish granules were observed in
177 lymphocytes and mucosal epithelial cells of the nasopharyngeal mucosa
178 (Fig 4A). In NPC tissues with downregulated PER2 protein expression,
179 only some lymphocytes were positive for PER2 expression (Fig 4B). In
180 NPC tissues positive for PER2 expression, lymphocytes and cancer cells
181 were both positive for PER2 expression (Fig 4C). Further analyses were
182 conducted to determine the correlation between PER2 expression in the
183 pathological specimens and the clinical characteristics of patients with NPC
184 (Table 3). No differences were observed in the rate of PER2 protein
185 expression positivity in terms of age, sex, or clinical NPC stage ($P > 0.05$).
186 However, PER2 expression was correlated with tumour T stage. The
187 positivity rate of PER2 expression decreased with an increase in the tumour
188 T stage. The PER2 positivity rate was significantly higher ($P < 0.05$) in T₁.

189 2 patients (45.45%) than in T₃₋₄ patients (9.09%).

190 Table 2 Expression of PER2 protein in nasopharyngeal carcinoma and

191 asopharyngeal mucosa

	PER2		P
	+	-	
Nasopharyngeal carcinoma	10(15.15%)	56(84.85%)	0.000
Nasopharyngeal mucosa	26(89.66%)	3(10.34%)	

192

193 Table 3 Expression of PER2 protein in nasopharyngeal carcinoma and its

194 clinical correlation

	PER2		P
	+	-	
Age			
	≤50	3(9.68%) 28(90.32%)	0.410
	>50	7(20.00%) 28(80.00%)	
Gender			
	male	9(19.15%) 38(80.85%)	0.296
	female	1(5.26%) 18(94.74%)	

T stage

T1-2	5(45.45%)	6(54.55%)	0.009
T3-4	5(9.09%)	50(90.91%)	

N stage

N0	0(0.00%)	4(100.00%)	0.510
N1-3	10(16.13%)	52(83.87%)	

M stage

M0	10(15.87%)	53(84.13%)	0.606
M1	0(0.00%)	3(84.13%)	

Clinical

stages

I+II	1(50.00%)	1(50.00%)	0.282
III +IV	9(14.06%)	55(85.94%)	

195

196 The positive expression rate of p-ERK protein in nasopharyngeal
 197 carcinoma tissues was 83.33% (55/66) and that in the nasopharyngeal
 198 mucosa was 24.14% (7/29), the both have significant difference ($P < 0.05$).
 199 (Table 4). In nasopharyngeal carcinoma and nasopharyngeal mucosa, the p-
 200 ERK protein is mainly expressed in the cytoplasm. Yellow or tan granules
 201 were observed in mucosal epithelial cells of the nasopharynx (Fig 5A). P-

202 ERK was negatively expressed in nasopharyngeal carcinomas (Fig 5B);
203 however, positive expression of p-ERK in cancer cells was observed in
204 nasopharyngeal carcinoma tissues with positive expression of the p-ERK
205 protein (Fig 5C). Further analysis of the correlation between the expression
206 levels of p-ERK protein in the pathological specimens and the clinical
207 features of patients with nasopharyngeal carcinoma was performed (Table
208 5). There was no significant difference between the expression levels of p-
209 ERK protein based on age, sex, and clinical stage of patients ($P > 0.05$);
210 however, the positive expression of p-ERK protein increased with the
211 increase in the N and M stages of tumors. The positive rate of N1-3 patients
212 (83.87%) was higher than that of N0 patients (75.00%), whereas the
213 positive rate of M1 patients (100.00%) was higher than that of M0 patients
214 (82.54%). The relationship between the expression levels of PER2 and p-
215 ERK in nasopharyngeal carcinoma tissues was also analyzed. Among the
216 p-ERK-positive cases, nine were positive for the PER2 protein, and one
217 case was negative for the p-ERK protein. Thus, the positive rate of PER2
218 protein expression in p-ERK-positive tumor tissues was low. The paired
219 chi-square test showed a statistically significant difference between the
220 expression levels of PER2 and p-ERK proteins in nasopharyngeal
221 carcinoma tissues ($P < 0.05$) (Table 6).
222 Table 4 Expression of p-ERK protein in nasopharyngeal carcinoma and
223 nasopharyngeal mucosa

		p-ERK		P
		+	-	
	Nasopharyngeal carcinoma	55(83.33%)	11(16.67%)	0.000
	Nasopharyngeal mucosa	7(24.14%)	22(75.86%)	
224	Table 5 Expression of p-ERK protein in nasopharyngeal carcinoma and its clinical correlation			
225				
226				
		p-ERK		P
		+	-	
	Age			
	≤50	27(87.10%)	4(12.90%)	0.440
	>50	28(80.00%)	7(20.00%)	
	Gender			
	male	39(82.98%)	8(17.02%)	0.608
	female	16(84.21%)	3(15.79%)	
	T stage			
	T ₁₋₂	10(90.91%)	1(9.09%)	0.768
	T ₃₋₄	45(81.82%)	10(18.18%)	

N stage

N ₀	3(75.00%)	1(25.00%)	0.527
N ₁₋₃	52(83.87%)	10(16.13%)	

M stage

M ₀	52(82.54%)	11(17.46%)	0.573
M ₁	3(100.00%)	0(0.00%)	

Clinical stages

I+II	1(50.00%)	1(50.00%)	0.308
III+IV	54(84.38%)	10(15.63%)	

227

228 Table 6 Relationship between PER2 protein and p-ERK protein expression
 229 in nasopharyngeal carcinoma

PER2	p-ERK		<i>P</i>
	+	-	
+	9	1	0.000
-	46	10	

230

231 **Discussion**

232 The occurrence and progression of NPC are caused by complex
233 genomic interactions between the environment, Epstein-Barr virus,
234 nasopharyngeal epithelial cells, immune cells, stroma, and the host (15).
235 Recent studies have provide novel insights into the progression of NPC.
236 p16 inactivation and cyclin D1 overexpression cause genomic changes,
237 promote cell growth, survival, and immune escape, while activating
238 oncogenes such as MYC. In NPC cells, several signalling pathways,
239 including the p53, EGFR-PI3K-Akt-Mtor, NOTCH, Wnt/ β -catenin, and
240 DNA damage repair pathways, are affected (16, 17). However,
241 interventions targeting a specific cellular signalling pathway cannot
242 provide sufficient information about the pathogenesis and treatment of
243 NPC. Presently, the treatment efficacy of NPC is poor, particularly in
244 advanced patients, and the side effects of treatment severely affect patient
245 quality of life. Therefore, further elucidation of the mechanisms underlying
246 NPC occurrence, progression, and recurrence and investigations of
247 biomarkers that can predict the prognosis and treatment response of
248 patients with NPC are of great significance to further improve the efficacy
249 of radiotherapy and chemotherapy, while reducing the adverse effects of
250 treatment.

251 Recent studies have confirmed that circadian clock genes are related
252 to the occurrence and development of various tumours, as well as the
253 sensitivity of tumour cells to anticancer drugs or radiation. Several

254 physiological activities, such as sleep, hormone levels, immunity, and
255 metabolism, are regulated by biological rhythms (18). Hence, biological
256 rhythm dysregulation may lead to abnormal cell proliferation, cell
257 resistance to apoptosis, and increased gene mutation rates, which may
258 induce tumorigenesis (19). Further studies have shown that changes in
259 biological rhythms are closely related to the occurrence of thyroid, breast,
260 prostate, colorectal, liver, lung, and other cancers (20-23). At the
261 mammalian cell level, the circadian rhythm system is a transcriptional
262 translation feedback loop based on the oscillatory compilation of circadian
263 clock gene expression (24, 25) and involves 14 core circadian clock genes
264 as well as various circadian clock control genes. *PER2* is a negative
265 regulator of the biological clock gene *BAM1* (26) and is primarily
266 expressed in the brain and external nervous system (27). It is also an
267 important negative feedback factor (28) that strictly regulates feedback
268 mechanisms, controls cell rhythms, and maintains normal physiological
269 function and metabolism in the human body. Studies have shown that
270 *PER2* dysregulation is related to the occurrence, development, treatment,
271 and prognosis of various tumours (29). In vitro studies in lung, breast,
272 pancreatic, and osteosarcoma cancers, as well as in LLC, EMT6, MG63,
273 Panc1, and Aspc1 cells, have demonstrated significant increases in tumour
274 cell apoptosis under *PER2* overexpression; however, cell proliferation and
275 metastasis were significantly reduced (30-32). A study on head and neck

276 squamous cell carcinomas confirmed that *PER2* dysregulation was related
277 to prognosis and chemotherapy sensitivity (33). In glioma cells, *PER2*
278 inhibits ID3 expression through the PTEN/AKT/Smad5 axis, thereby
279 further inhibiting the proliferation of glioma cells. *PER2* is dysregulated,
280 resulting in increased ID3 expression, which is positively correlated with
281 WHO grade and poorer prognoses(34). *PER2* can also act on various key
282 checkpoints in the cell cycle and regulate cell proliferation and apoptosis
283 (35). *PER2* mutant mice show increased c-Myc and decreased p53 gene
284 expression, which play vital roles in regulating the G1-S checkpoint of the
285 cell cycle (36). Furthermore, studies have shown that expression levels of
286 *PER* gene family members can be used as prognostic markers for head and
287 neck squamous cell carcinomas (37). However, the mechanisms that
288 govern the relationship between *PER2* and NPC development have not
289 been reported previously.

290 Earlier in our research, we found that *PER2* overexpression could
291 inhibit the proliferation, migration, and invasion of NPC cells, as well as
292 their tumorigenicity in nude mice(14). *PER2* overexpression also inhibited
293 cell cycle progression in NPC cells, while promoting apoptosis. Thus, it
294 was suggested that *PER2* acts as a tumour suppressor in NPC. In this study,
295 we further studied the proteomics of NPC cell lines by overexpressing
296 *PER2*. *PER2* overexpression downregulated ERK phosphorylation. Studies
297 have shown that ERK and p38MAPK, members of the MAPK family, are

298 involved in cell proliferation, differentiation, migration, ageing, apoptosis,
299 and other processes in various tumours (38-40). The classical MAPK
300 activation pathway activates GTP proteins (RAS) via exogenous
301 stimulation. MAPK kinase is phosphorylated by a cascade that ultimately
302 activates ERK. The activated ERK protein then enters the nucleus and
303 activates nuclear transcription factors. Throughout the entire cascade
304 activation process, ERK is regulated by other factors such as TGF and
305 Smad5 (41). The ERK/MAPK pathway primarily regulates cell
306 differentiation, proliferation, and apoptosis by regulating activities
307 including cell cycle progression, cell survival, and apoptosis-related
308 proteins downstream of this pathway. Abnormal activation of this pathway
309 is closely related to the occurrence and development of various tumours,
310 such as NPC and liver cancer (42).

311 Studies have also shown that *PER2* plays an important role in the
312 post-translational modification of various proteins. *PER2* is involved in the
313 ubiquitination of p53 and hypoxia-inducible factor 1, thereby affecting
314 their degradation. *PER2* can competitively bind to ubiquitinated enzyme
315 sites on p53 and other proteins, inhibiting the binding of ubiquitinated
316 enzymes such as MDM2 to p53 and maintaining the stability of p53 (43,
317 44). Few studies have investigated the effects of *PER2* phosphorylation on
318 downstream proteins. p38 phosphorylation rates vary rhythmically in
319 gliomas. When the biological rhythm is disturbed, phosphorylation is

320 disrupted, and high expression is observed, which may correlate with the
321 invasiveness of tumour cells (45).

322 Further analysis of *PER2* and p-ERK expression levels in NPC tissues
323 and normal nasopharyngeal mucosa samples revealed low *PER2* expression
324 in NPC tissues and high p-ERK expression. The relationships between
325 *PER2*, p-ERK, and clinical characteristics of NPC patients were analysed.
326 The results showed that *PER2* expression was related to the T stage of
327 tumours, suggesting that *PER2* expression may be related to the local
328 invasiveness of NPCs. The positivity rate of p-ERK expression increased
329 with an increase in tumour N and M stages. Furthermore, *PER2* expression
330 was associated with p-ERK expression in NPC, suggesting that the
331 regulation of p-ERK by *PER2* may be related to the invasion and
332 metastasis of NPC. However, this study does have limitations such as the
333 small clinical sample size and potential biases in the experimental results.
334 In future studies, we hope to expand the sample size and further clarify the
335 expression characteristics and role of *PER2* in NPC.

336 **Conclusions**

337 In conclusion, overexpression of *PER2* inhibited tumor development
338 by downregulating the phosphorylation of ERK/MAPK in NPC cells. The
339 modulation of the ERK/MAPK signalling pathway by regulating *PER2*
340 expression may be a promising strategy for chronotherapy of NPC.

341 **Acknowledgments**

342 Hailiang Li and Li Hou designed the work. Zhijuan Zhang and Zheng
343 Ma contributed to the acquisition and analysis of data and manuscript
344 writing. Jing Kang, Jing Yang, Qianru Xu, Xinran Niu, Xiaoya Luo and
345 Jingyuan Wang contributed to analysis and data interpretation. All authors
346 approved the submitted version.

347 **Data availability statement**

348 The data that support the findings of this study are available from the
349 corresponding author upon reasonable request.

350 **Ethical Approval**

351 This study was approved by the ethics committee of the General
352 Hospital of Ningxia Medical University(Ethics Number: KYLL-2021-
353 1023), and all patients signed written informed consent.

354 **References**

- 355 1. Tsang RK. Nasopharyngeal carcinoma - Improving cure with
356 technology and clinical trials. World journal of otorhinolaryngology - head
357 and neck surgery. 2020;6(1):1-3.
- 358 2. Li YQ, Chen Y, Xu YF, He QM, Yang XJ, Li YQ, et al. FNDC3B 3'-
359 UTR shortening escapes from microRNA-mediated gene repression and
360 promotes nasopharyngeal carcinoma progression. Cancer science.
361 2020;111(6):1991-2003.

- 362 3. Yeh CF, Chin YC, Huang WH, Lan MY. Prior cancer history predicts
363 the worse survival of patients with nasopharyngeal carcinoma. *European*
364 *archives of oto-rhino-laryngology : official journal of the European*
365 *Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with*
366 *the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery.*
367 2022;279(11):5381-7.
- 368 4. Vitale JA, Lombardi G, Weydahl A, Banfi G. Biological rhythms,
369 chronodisruption and chrono-enhancement: The role of physical activity as
370 synchronizer in correcting steroids circadian rhythm in metabolic
371 dysfunctions and cancer. *Chronobiol Int.* 2018;35(9):1185-97.
- 372 5. Bishehsari F, Engen PA, Voigt RM, Swanson G, Shaikh M, Wilber S,
373 et al. Abnormal Eating Patterns Cause Circadian Disruption and Promote
374 Alcohol-Associated Colon Carcinogenesis. *Cellular and molecular*
375 *gastroenterology and hepatology.* 2020;9(2):219-37.
- 376 6. Ali YF, Hong Z, Liu NA, Zhou G. Clock in radiation oncology clinics:
377 cost-free modality to alleviate treatment-related toxicity. *Cancer biology &*
378 *therapy.* 2022;23(1):201-10.
- 379 7. Wang Z, Wang H, Guo H, Li F, Wu W, Zhang S, et al. The circadian
380 rhythm and core gene *Period2* regulate the chemotherapy effect and
381 multidrug resistance of ovarian cancer through the PI3K signaling pathway.
382 *Bioscience reports.* 2020;40(11).
- 383 8. Morales-Santana S, Morell S, Leon J, Carazo-Gallego A, Jimenez-

- 384 Lopez JC, Morell M. An Overview of the Polymorphisms of Circadian
385 Genes Associated With Endocrine Cancer. *Frontiers in endocrinology*.
386 2019;10:104.
- 387 9. Chang AM, Duffy JF, Buxton OM, Lane JM, Aeschbach D, Anderson
388 C, et al. Chronotype Genetic Variant in PER2 is Associated with Intrinsic
389 Circadian Period in Humans. *Scientific reports*. 2019;9(1):5350.
- 390 10. Tang Q, Xie M, Yu S, Zhou X, Xie Y, Chen G, et al. Periodic
391 Oxaliplatin Administration in Synergy with PER2-Mediated PCNA
392 Transcription Repression Promotes Chronochemotherapeutic Efficacy of
393 OSCC. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany).
394 2019;6(21):1900667.
- 395 11. Wang Z, Li F, Wei M, Zhang S, Wang T. Circadian Clock Protein
396 PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin
397 Sensitivity in Ovarian Cancer. *Cancer management and research*.
398 2020;12:11897-908.
- 399 12. Fagiani F, Di Marino D, Romagnoli A, Travelli C, Voltan D, Di
400 Cesare Mannelli L, et al. Molecular regulations of circadian rhythm and
401 implications for physiology and diseases. *Signal transduction and targeted*
402 *therapy*. 2022;7(1):41.
- 403 13. Zhang P, He Q, Wang Y, Zhou G, Chen Y, Tang L, et al. Protein C
404 receptor maintains cancer stem cell properties via activating lipid synthesis
405 in nasopharyngeal carcinoma. *Signal transduction and targeted therapy*.

406 2022;7(1):46.

407 14. Hou L, Li H, Wang H, Ma D, Liu J, Ma L, et al. The circadian clock
408 gene PER2 enhances chemotherapeutic efficacy in nasopharyngeal
409 carcinoma when combined with a targeted nanosystem. Journal of materials
410 chemistry B. 2020;8(24):5336-50.

411 15. Campion NJ, Ally M, Jank BJ, Ahmed J, Alusi G. The molecular
412 march of primary and recurrent nasopharyngeal carcinoma. Oncogene.
413 2021;40(10):1757-74.

414 16. Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Nasopharyngeal Cancer:
415 Molecular Landscape. Journal of clinical oncology : official journal of the
416 American Society of Clinical Oncology. 2015;33(29):3346-55.

417 17. Chow YP, Tan LP, Chai SJ, Abdul Aziz N, Choo SW, Lim PV, et al.
418 Exome Sequencing Identifies Potentially Druggable Mutations in
419 Nasopharyngeal Carcinoma. Scientific reports. 2017;7:42980.

420 18. Chicurel M. Circadian rhythms. Mutant gene speeds up the human
421 clock. Science (New York, NY). 2001;291(5502):226-7.

422 19. Zhou L, Zhang Z, Nice E, Huang C, Zhang W, Tang Y. Circadian
423 rhythms and cancers: the intrinsic links and therapeutic potentials. Journal
424 of hematology & oncology. 2022;15(1):21.

425 20. Zhang L, Chen Y, Chong CS, Ma X, Tong S, He X, et al. The genomic
426 and transcriptomic landscapes of clock genes reveal the significance of
427 circadian rhythm in the progression and immune microenvironment of

- 428 metastatic colorectal cancer. *Clinical and translational medicine*.
429 2022;12(3):e755.
- 430 21. Feng D, Xiong Q, Zhang F, Shi X, Xu H, Wei W, et al. Identification
431 of a Novel Nomogram to Predict Progression Based on the Circadian Clock
432 and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
433 *Frontiers in immunology*. 2022;13:777724.
- 434 22. Zhang H, Liu R, Zhang B, Huo H, Song Z. Advances in the Study of
435 Circadian Genes in Non-Small Cell Lung Cancer. *Integrative cancer*
436 *therapies*. 2022;21:15347354221096080.
- 437 23. Xu T, Jin T, Lu X, Pan Z, Tan Z, Zheng C, et al. A signature of
438 circadian rhythm genes in driving anaplastic thyroid carcinoma malignant
439 progression. *Cellular signalling*. 2022;95:110332.
- 440 24. Ruan W, Yuan X, Eltzschig HK. Circadian rhythm as a therapeutic
441 target. *Nature reviews Drug discovery*. 2021;20(4):287-307.
- 442 25. Lee SF, Luque-Fernandez MA. Is cancer-related death associated with
443 circadian rhythm? *Cancer communications (London, England)*.
444 2019;39(1):27.
- 445 26. Kim YH, Lazar MA. Transcriptional Control of Circadian Rhythms
446 and Metabolism: A Matter of Time and Space. *Endocrine reviews*.
447 2020;41(5):707-32.
- 448 27. Kim M, de la Peña JB, Cheong JH, Kim HJ. Neurobiological
449 Functions of the Period Circadian Clock 2 Gene, Per2. *Biomolecules &*

- 450 therapeutics. 2018;26(4):358-67.
- 451 28. Shostak A. Circadian Clock, Cell Division, and Cancer: From
452 Molecules to Organism. International journal of molecular sciences.
453 2017;18(4).
- 454 29. Fekry B, Eckel-Mahan K. The circadian clock and cancer: links
455 between circadian disruption and disease Pathology. Journal of biochemistry.
456 2022;171(5):477-86.
- 457 30. Hernández-Rosas F, López-Rosas CA, Saavedra-Vélez MV.
458 Disruption of the Molecular Circadian Clock and Cancer: An Epigenetic
459 Link. Biochemical genetics. 2020;58(1):189-209.
- 460 31. Cheng AY, Zhang Y, Mei HJ, Fang S, Ji P, Yang J, et al. Construction
461 of a plasmid for overexpression of human circadian gene period2 and its
462 biological activity in osteosarcoma cells. Tumour biology : the journal of the
463 International Society for Oncodevelopmental Biology and Medicine.
464 2015;36(5):3735-43.
- 465 32. Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan
466 R, et al. Loss of circadian clock gene expression is associated with tumor
467 progression in breast cancer. Cell cycle (Georgetown, Tex).
468 2014;13(20):3282-91.
- 469 33. Rahman S, Kraljević Pavelić S, Markova-Car E. Circadian
470 (De)regulation in Head and Neck Squamous Cell Carcinoma. International
471 journal of molecular sciences. 2019;20(11).

- 472 34. Zhang X, Liu T, Huang J, He J. PICALM exerts a role in promoting
473 CRC progression through ERK/MAPK signaling pathway. *Cancer cell*
474 *international*. 2022;22(1):178.
- 475 35. Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian
476 timing in cancer treatments. *Annual review of pharmacology and toxicology*.
477 2010;50:377-421.
- 478 36. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene *Period2*
479 plays an important role in tumor suppression and DNA damage response in
480 vivo. *Cell*. 2002;111(1):41-50.
- 481 37. Li YY, Jin F, Zhou JJ, Yu F, Duan XF, He XY, et al. Downregulation
482 of the circadian *Period* family genes is positively correlated with poor head
483 and neck squamous cell carcinoma prognosis. *Chronobiol Int*.
484 2019;36(12):1723-32.
- 485 38. Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway
486 of MAPK/ERK in cell proliferation, differentiation, migration, senescence
487 and apoptosis. *Journal of receptor and signal transduction research*.
488 2015;35(6):600-4.
- 489 39. Sun QY, Ding LW, Johnson K, Zhou S, Tyner JW, Yang H, et al.
490 SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells.
491 *Oncogene*. 2019;38(34):6196-210.
- 492 40. Li A, Shi D, Xu B, Wang J, Tang YL, Xiao W, et al. S100A6 promotes
493 cell proliferation in human nasopharyngeal carcinoma via the p38/MAPK

- 494 signaling pathway. *Molecular carcinogenesis*. 2017;56(3):972-84.
- 495 41. Du M, Chen W, Zhang W, Tian XK, Wang T, Wu J, et al. TGF-?
496 regulates the ERK/MAPK pathway independent of the SMAD pathway by
497 repressing miRNA-124 to increase MALAT1 expression in nasopharyngeal
498 carcinoma. *Biomedicine & pharmacotherapy = Biomedecine &
499 pharmacotherapie*. 2018;99:688-96.
- 500 42. Wang LH, Li Y, Yang SN, Wang FY, Hou Y, Cui W, et al. Gambogic
501 acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell
502 lung cancer through suppressing NF- κ B and MAPK/HO-1 signalling. *British
503 journal of cancer*. 2014;110(2):341-52.
- 504 43. Gotoh T, Kim JK, Liu J, Vila-Caballer M, Stauffer PE, Tyson JJ, et
505 al. Model-driven experimental approach reveals the complex regulatory
506 distribution of p53 by the circadian factor Period 2. *Proceedings of the
507 National Academy of Sciences of the United States of America*.
508 2016;113(47):13516-21.
- 509 44. Farshadi E, van der Horst GTJ, Chaves I. Molecular Links between
510 the Circadian Clock and the Cell Cycle. *Journal of molecular biology*.
511 2020;432(12):3515-24.
- 512 45. Goldsmith CS, Kim SM, Karunarathna N, Neuendorff N, Toussaint
513 LG, Earnest DJ, et al. Inhibition of p38 MAPK activity leads to cell type-
514 specific effects on the molecular circadian clock and time-dependent
515 reduction of glioma cell invasiveness. *BMC cancer*. 2018;18(1):43.




Fig 1. Differential protein expression information

Fig 1




Fig 2. Heat map of top20 differential protein between PER2 overexpression group and control

Fig 2




Fig 3. The protein expression of ERK 、 p-ERK in PER2-OE and Control group cells. Three samples were extracted from each PER2-OE and Control groups for sample loading testing.

Fig 3




Fig 4. Expression of PER2 protein in nasopharyngeal carcinoma and nasopharyngeal mucosa.

A. The positive expression of PER2 protein in nasopharyngeal mucosa. B. The expression of PER2 protein was negative in nasopharyngeal carcinoma. C. The positive expression of PER2 protein in nasopharyngeal carcinoma.




Fig 5. Expression of p-ERK protein in nasopharyngeal carcinoma and nasopharyngeal mucosa.

A. The positive expression of p-ERK protein in nasopharyngeal mucosa. B. The expression of p-ERK protein was negative in nasopharyngeal carcinoma. C. The positive expression of p-ERK protein in nasopharyngeal carcinoma.